ASCO Meeting 2024 Participation

**2024 Young Investigator Award Recipients**

Rebecca Forman, MD

Yiduo Hu, MD, PhD

Tendai Kwaramba, MD, MSc

**ASCO Education Scholar**

Thejal Srikumar, MD

**Friday, May 31**

**Workshop**

In-Person Workshop: Genomics 101 for Oncologists

**Medical Oncologist Perspective**

May 31; 1:00 – 5:00 PM CDT

Presenter: Michael E. Hurwitz, MD, PhD

Location: S105ab

**Saturday, June 1**

**Oral Abstract**

Genitourinary Cancer—Kidney and Bladder

*Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).*

June 1; 8:42 – 8:48AM CDT

Presenter: Soki Kashima

Senior Author: David Braun

Location: S100bc | Abstract 4515

**Poster Session**
Poster Session
Developmental Therapeutics—Immunotherapy
**SH2B3 mutation as a potential resistance mechanism to oncolytic virus therapy.**
June 1; 9:00 – 12:00PM CDT
Presenter: Philippos Costa
Location: Hall A | Abstract 2578 | Poster Bd 57

Poster Session
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
**Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.**
June 1; 9:00 – 12:00PM CDT
Author: Pamela Kunz
Location: Hall A | Abstract 3091 | Poster Bd 236

Poster Session
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
**Comprehensive characterization of ERBB2 genomic alterations in lung cancer.**
June 1; 9:00 – 12:00PM CDT
Presenter: Talal El Zarif
Location: Hall A | Abstract 3148 | Poster Bd 293

Poster Session
Sarcoma
**Sorafenib treatment duration in desmoid tumors.**
June 1; 1:30 – 4:30PM CDT
Presenter: Philippos Costa
Location: Hall A | Abstract 11585 | Poster Bd 511

Poster Session
Central Nervous System Tumors
**Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.**
Presenter: Nicholas Blondin
June 1; 9:00 – 12:00PM CDT
Location: Hall A | Abstract: 2029 | Poster Bd 328

Poster Session
Developmental Therapeutics—Immunotherapy
**Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.**
June 1; 9:00 – 12:00PM CDT
Presenter: Alexander Frey
Senior Author: Jeffrey Ishizuka
Location: Hall A | Abstract 2637 | Poster Bd 116

Poster Session
Developmental Therapeutics—Immunotherapy
A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.
June 1; 9:00 – 12:00PM CDT
Senior Author: Barbara Burtness
Location: Hall A | Abstract TPS2701 | Poster Bd 164a

Poster Session
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
June 1; 9:00 – 12:00 PM CDT
Senior Author: Patricia LoRusso
Location: Hall A | Abstract TPS3183 | Poster Bd 316a

Poster Session
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.
June 1; 9:00 – 12:00PM CDT
Presenter: Aarti Bhatia
Location: Hall A | Abstract TPS3164 | Poster Bd 307a

Education Session
Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates
Role of Payload and Antibody in Predicting Resistance to Antibody-Drug Conjugates
June 1; 1:15 – 2:30PM CDT
Presenter: Patricia LoRusso
Location: Hall D1

Education Session
Tackling the Tough Stuff: Managing Challenging Symptoms and Patient Conversations Around Goals of Care
Primary Palliative Care Skills: How to Integrate Into Your Oncology Practice
June 1; 1:15 – 1:30PM CDT
Presenter: Jennifer Kapo
Location: E450a

Education Session
State-of-the-Art Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma: Current Advances and Future Frontiers
Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches
June 1; 1:30 – 1:45 PM CDT
Presenter: David Braun
Location: Hall D2

Poster Session
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).**

June 1; 1:30 – 4:30PM CDT
Presenter: Jacquelyne Gaddy
Location: Hall A | Abstract 4138 | Poster Bd 118

**Poster Session**
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.**

June 1; 1:30 – 4:30PM CDT
Presenter: Pamela Kunz
Location: Hall A | Abstract 4131 | Poster Bd 111

**Poster Session**
Melanoma/Skin Cancers

**Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials.**

June 1; 1:30 – 4:30PM CDT
Presenter: Thazin Aung
Location: Hall A | Abstract 9567 | Poster Bd 351

**Education Session**
Advanced Lung Cancer: State-of-the-Art Approaches and Insights

**Small Cell Lung Cancer**
June 1; 3:00 – 3:15 PM CDT
Presenter: Anne C. Chiang
Location: S406

**Oral Abstract**
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2– breast cancer.**

June 1; 4:24 – 4:36PM CDT
Presenter: Pat LoRusso
Location: Hall D1 | Abstract 3006

**Education Session**
Navigating the Complexities of Brain Metastases Management

June 1; 4:45 -6:00 PM CDT
Chair: Sarah B. Goldberg, MD
Location: E450a

**Education Session**
Has the Revolution in Precision Medicine Reached Patients With Brain Metastases?
June 1; 4:45 -5:00 PM CDT
Sunday, June 2

Oral Abstract
Gastrointestinal Cancer—Colorectal and Anal
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
June 2; 10:24 – 10:36 AM CDT
Senior Author: Michael Cecchini
Location: Arie Crown Theater | Abstract 3508

Poster Session
Genitourinary Cancer—Kidney and Bladder
Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).
June 2; 9:00 – 12:00PM CDT
Senior Author: David Braun
Location: Hall A | Abstract 4546 | Poster Bd 241

Poster Session
Genitourinary Cancer—Kidney and Bladder
A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.
June 2; 9:00 – 12:00PM CDT
Senior Author: Dan Petrylak
Location: Hall A | Abstract TPS4619 | Poster Bd 308a

Poster Session
Breast Cancer—Local/Regional/Adjuvant
Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer. article
June 2; 9:00 – 12:00PM CDT
Presenter: Daniel O’Neil
Location: Hall A | Abstract 522 | Poster Bd 114

Poster Session
Breast Cancer
Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.
June 2; 9:00 – 12:00PM CDT
Senior Author: Maryam Lustberg
Location: Hall A | Abstract 1065 | Poster Bd 43

Poster Session
Head and Neck Cancer
Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study.
June 2; 9:00 – 12:00 PM CDT
Senior Author: Joseph Kim
Location: Hall A | Abstract 6079 | Poster Bd 395

Poster Session
Breast Cancer
Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
June 2; 9:00 – 12:00PM CDT
Presenter: Nicole Odzer
Location: Hall A | Abstract 1104 | Poster Bd 82

Poster Session
Breast Cancer—Metastatic
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).
June 2; 9:00 – 12:00PM CDT
Presenter: Melissa Taylor
Location: Hall A | Abstract 1092 | Poster Bd 70

Poster Session
Breast Cancer—Local/Regional/Adjuvant
Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.
June 2; 9:00 – 12:00PM CDT
Presenter: Alejandro Rios-Hoyo
Location: Hall A | Abstract 573 | Poster Bd 165

Case-Based Panel
Radiation Oncologist Perspective
June 2; 11:30 AM CDT
Presenter: Henry Soo-Min Park
Location: Hall D1

Clinical Science Symposium
Care Delivery and Quality Care
Navigating Global Cancer Care: Conflict, Access, and Delivery
**Oral Abstract**
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

*Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).*

June 2; 4:30 – 6:00PM CDT
Presenter: Ritujith Jayakrishnan
Location: S406 | Abstract 8013

---

**Monday, June 3**

**Oral Abstract**
Genitourinary Cancer—Kidney and Bladder

*Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.*

June 3; 8:24 – 8:36AM CDT
Presenter: Daniel Petrylak
Location: Hall B1 | Abstract 4503

---

**Poster Session**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

*Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.*

June 3; 9:00 – 12:00PM CDT
Presenter: Amer Zeidan
Location: Hall A | Abstract 6565 | Poster Bd 124

---

**Poster Session**
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

*Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.*

June 3; 9:00 – 12:00PM CDT
Presenter: Amer Zeidan
Location: Hall A | Abstract 6566 | Poster Bd 125

---

**Poster Session**
Hematologic Malignancies—Plasma Cell Dyscrasia

*Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).*

June 3; 9:00 – 12:00PM CDT
Presenter: Poy Theprungsirikul
Location: Hall A | Abstract 7549 | Poster Bd 186
**Poster Session**
Quality Care/Health Services Research
*Oral cancer drug repositories: Challenges and solutions.*
June 3; 9:00 – 12:00PM CDT
Senior Author: Osama Abdelghany
Location: Hall A | Abstract 11063 | Poster Bd 258

**Poster Session**
Quality Care/Health Services Research
*Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.*
June 3; 9:00 – 12:00PM CDT
Presenter: Laura Baum
Location: Hall A | Abstract 447678 | Poster Bd 254

**Poster Session**
Quality Care/Health Services Research
*Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.*
June 3; 9:00 – 12:00PM CDT
Senior Author: Maureen Canavan
Location: Hall A | Abstract 11092 | Poster Bd 287

**Poster Session**
Hematologic Malignancies—Plasma Cell Dyscrasia
*Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.*
June 3; 9:00 – 12:00PM CDT
Presenter: Sabrina Browning
Location: Hall A | Abstract 7559 | Poster Bd 196

**Oral Abstract**
Medical Education and Professional Development
*Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.*
Presenter: Thejal Srikumar
June 3; 9:51 – 9:57AM CDT
Location: E450a | Abstract 9004

**Oral Abstract**
Medical Education and Professional Development
*Evaluating speaker gender in scientific sessions at ASCO and ASCO GI (2019-2023)*
Author: Pamela Kunz
June 3; 10:45 – 10:51 AM CDT
Location: E450a | Abstract 9009

**Oral Abstract**
Genitourinary Cancer—Prostate, Testicular, and Penile

**ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.**
June 3; 1:27 – 1:33PM CDT
Presenter: Daniel Petrylak
Location: Hall B1 | Abstract 5011

**Poster Session**
Symptom Science and Palliative Care

**Factors associated with sexual function and sexual satisfaction in young women with breast cancer.**
June 3; 1:30 – 4:30PM CDT
Presenter: Ana Ferrigno Guajardo
Location: Abstract 12062 | Poster Bd 191

**Poster Session**
Lung Cancer

**Updated results from COAST, a phase 2 study of durvalumab (D) + oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).**
June 3; 1:30 – 4:30PM CDT
Senior Author: Roy Herbst
Location: Hall A | Abstract 8046 | Poster Bd 308

**Poster Session**
Prevention, Risk Reduction, and Genetics

**Estimating risk for pancreatic cancer among 9.4 million veterans in care.**
June 3; 1:30 – 4:30PM CDT
Presenter: Louise Wang
Location: Hall A | Abstract 10544 | Poster Bd 71

**Poster Session**
Lung Cancer

**Lymph node metastasis prediction with non-small cell lung cancer histopathology imaging.**
Presenter: Victor Lee
June 3; 1:30 – 4:30PM CDT
Location: Hall A | Abstract 8063 | Poster Bd 325

**Poster Session**
Prevention, Risk Reduction, and Genetics

**Associations between violence, distress, and cancer in transgender and non-transgender people.**
June 3; 1:30 – 4:30PM CDT
Presenter: Ash Alpert
Location: Abstract 10566 | Poster Bd 93

**Poster Session**
Prevention, Risk Reduction, and Genetics

**Population attributable fraction of reproductive factors in triple negative breast cancer by race.**
June 3; 1:30 – 4:30PM CDT
Presenter: Rachel Jaber Chehayeb
Poster Session
Symptom Science and Palliative Care
Neurofilament light chains: A biomarker for vincristine-related neuropathy.
June 3; 1:30 – 4:30PM CDT
Senior Author: Maryam Lustberg
Location: Hall A | Abstract 12114 | Poster Bd 243

Poster Session
Prevention, Risk Reduction, and Genetics
Blood type as a risk factor for pancreatic ductal adenocarcinoma.
June 3; 1:30 – 4:30PM CDT
Presenter: Navid Rahimi Larki
Location: Hall A | Abstract 10559 | Poster Bd 86

Poster Session
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
June 3; 1:30 – 4:30PM CDT
Presenter: Amin Nassar
Location: Hall A | Abstract 8106 | Poster Bd 368

Poster Session
Lung Cancer—Non-Small Cell Metastatic
Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.
June 3; 1:30 – 4:30PM CDT
Presenter: Kelsey Matteson
Location: Hall A | Abstract 8602 | Poster Bd 466

Clinical Science Symposium
Making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer
June 3; 3:12 – 3:24PM CDT
Presenter: Barbara Burtness
Location: E451 | Abstract 6009

Education Session
Shaping the Future of Cancer Care: Diverse Perspectives on Emerging Health Policies
Impact of Emerging Legislation on Cancer Care—A Hospital-Based Perspective
June 3; 3:15 – 3:30 PM CDT
Presenter: Osama Abdelghany
Location: S102
**Oral Abstract**
Breast Cancer—Local/Regional/Adjuvant
*Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.*
June 3; 5:24 – 5:36PM CDT
Presenter: Lajos Pusztai
Location: Hall B1 | Abstract 508

**Tuesday, June 4**

**Oral Abstract Session**
Head and Neck Cancer
Chair: Aarti K. Bhatia
June 4; 9:45 – 12:45PM CDT
Location: S100a | Live Stream

**Oral Abstract**
Head and Neck Cancer
*A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).*
June 4; 10:57 – 11:09AM CDT
Senior Author: Sara Pai
Location: S100a | Abstract 6004

**Publications Only**

**Publication Only**
Central Nervous System Tumors
*HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer.*
Senior Author: Kurt Schalper
Location: Abstract e14014

**Publication Only**
Care Delivery/Models of Care
*Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.*
Senior Author: Neal Fischbach
Location: Abstract e13586

**Publication Only**
Pediatric Oncology
*Modeling response to alkylating chemotherapy in a syngeneic model of MMR-deficient glioma.*
Senior Author: Deepti Bhatt
Location: Abstract e22001
Breast Cancer
Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer.
Senior Author: Maryam Lustberg
Location: Abstract #e12639

Sarcoma
Senior Author: Philippos Costa
Location: Abstract #e23528

Melanoma/Skin Cancers
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.
Author: Daniel Lee
Location: Abstract e21522

Symptom Science and Palliative Care
Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.
Author: Neal Fischbach
Location: Abstract e24140

Care Delivery and Quality Care
Personalized risk assessment of new onset depression in long-term cancer survivors.
Article
Author: Melissa Taylor
Location: Abstract e13798

Medical Education and Professional Development
A medical school curriculum to foster the physician-patient relationship through narrative medicine.
Article
Author: Johnathan Yao
Location: Abstract e21015

Care Delivery/Models of Care
The unmet needs of women with metastatic breast cancer in Mexico: A qualitative study.
Author: Ana Ferrigno Guajardo
Location: Abstract e13547
Publication Only
Lung Cancer
Real world outcomes of patients with small cell lung cancer (SCLC) presenting with brain metastasis at diagnosis in a single institution health system.
Author: Julia Joseph
Location: Abstract: e20136